Skip to main content
锦好医疗 logo

锦好医疗 — Investor Relations & Filings

Ticker · 920925 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2025-04-28 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920925

About 锦好医疗

https://www.jinghao.cn/

Jinghao Medical specializes in the research, development, and manufacturing of hearing aids and home medical electronic products. The company's core portfolio includes digital and analog hearing aids, medical nebulizers, and electronic blood pressure monitors. It focuses on providing hearing health solutions by integrating advanced digital signal processing technology into its devices. Jinghao Medical operates extensively in the global market, offering original design manufacturing (ODM) and original equipment manufacturing (OEM) services to international partners. The organization emphasizes technological innovation and maintains rigorous quality management systems to comply with international medical device standards. Its primary objective is to deliver accessible, high-performance medical equipment designed to improve the quality of life for users with hearing loss and other chronic health conditions.

Recent filings

Filing Released Lang Actions
第三届董事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the company's board of directors regarding the approval of the company's 2025 first quarter report. It references the actual quarterly report (2025 first quarter report) which is disclosed separately on the official exchange platform. The document itself does not contain the financial data or the full quarterly report but is an announcement of the board meeting decisions and resolutions. The document length is short (963 characters) and it states that the quarterly report is available elsewhere. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of board resolutions related to a report, not the report itself.
2025-04-28 Chinese
第三届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of Huizhou Jin Hao Medical Technology Co., Ltd. It details the convening and attendance of the third Supervisory Board's seventh meeting and the approval of the company's 2025 first quarter report. The document references the actual 2025 first quarter report being disclosed separately on the Beijing Stock Exchange platform (announcement number 2025-035). The current document does not contain the financial data or substantive analysis of the quarterly report itself but is an announcement of the meeting resolution approving that report. The document length is short (771 characters), and it serves as a formal announcement of the meeting decision rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the Interim/Quarterly Report (IR) itself.
2025-04-28 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 年第一季度报告" which translates to "2025 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period January to March 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It is unaudited but contains substantive financial data and management commentary on financial results and business trends. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-28 Chinese
第三届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the ninth meeting of the third board of directors of Huizhou Jin Hao Medical Technology Co., Ltd. It includes voting results on various proposals such as the 2024 annual report, 2024 audit report, board work report, general manager's work report, independent directors' reports, financial budget, equity distribution plan, stock incentive plans, internal control reports, and other governance matters. The document repeatedly references that the actual reports are disclosed separately on the Beijing Stock Exchange information disclosure platform with specific announcement numbers. The document is a formal board meeting resolution announcement, not the reports themselves. It also includes procedural details about the meeting and voting, which is typical for board/management information disclosures. Therefore, this document fits best under the category of Board/Management Information (MANG).
2025-04-21 Chinese
2024年独立董事述职报告（丘小乐）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" from Huizhou Jin Hao Medical Technology Co., Ltd. It details the independent director's attendance at board and committee meetings, voting records, communication with internal audit and accounting firms, and efforts to protect investor rights during the 2024 fiscal year. The content focuses on the independent director's duties and activities rather than presenting financial statements or audit results. The document length is 2071 characters, which is relatively short and more of a narrative report on director activities rather than a formal audit or annual report. This type of document fits best under Board/Management Information (MANG) as it relates to board member duties and disclosures rather than financial results or audit opinions.
2025-04-21 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an '年度报告摘要' which translates to 'Annual Report Summary'. It contains detailed financial data for the year 2024, including assets, net profit, earnings per share, and shareholder information. It also includes management assurances about the accuracy of the report and mentions an audit report with an unqualified opinion. The length of the document (5622 characters) and the presence of substantive financial data and company operational details indicate this is the actual annual report content, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2024
2025-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.